Belite Bio Inc ADR Asset Resilience Ratio
Belite Bio Inc ADR asset resilience ratio. Belite Bio Inc ADR (BLTE) has an Asset Resilience Ratio of 17.87% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read Belite Bio Inc ADR balance sheet liabilities for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Belite Bio Inc ADR (2023–2025)
Asset resilience ratio of Belite Bio Inc ADR from 2023 to 2025. This chart shows how Belite Bio Inc ADR's Asset Resilience Ratio has changed over time. See Belite Bio Inc ADR free cash flow ratio to measure how efficiently the company converts operating cash flow to free cash.
Liquid Assets Composition Over Time
This chart breaks down Belite Bio Inc ADR's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see how large is Belite Bio Inc ADR's balance sheet.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $139.49 Million | 17.87% |
| Total Liquid Assets | $139.49 Million | 17.87% |
Asset Resilience Insights
- Good Liquidity Position: Belite Bio Inc ADR maintains a healthy 17.87% of assets in liquid form.
- This level provides good financial flexibility while maintaining productive asset deployment.
- The company has significant short-term investments, indicating active treasury management.
Belite Bio Inc ADR Industry Peers by Asset Resilience Ratio
Compare Belite Bio Inc ADR's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
argenx NV ADR
NASDAQ:ARGX |
Biotechnology | 15.95% |
|
89bio Inc
NASDAQ:ETNB |
Biotechnology | 71.60% |
|
Eikon Therapeutics, Inc. Common Stock
NASDAQ:EIKN |
Biotechnology | 49.84% |
|
Jiangsu Bioperfectus Technologies Co Ltd
SHG:688399 |
Biotechnology | 37.23% |
|
Larimar Therapeutics Inc
NASDAQ:LRMR |
Biotechnology | 38.46% |
|
Hyloris Developmentsen Sa
BR:HYL |
Biotechnology | 1.36% |
|
Equillium Inc
NASDAQ:EQ |
Biotechnology | 0.00% |
|
iNtRON Biotechnology Inc
KQ:048530 |
Biotechnology | 10.90% |
Belite Bio Inc ADR Asset Resilience Ratio by Year (2023–2025)
Belite Bio Inc ADR asset resilience ratio by year from 2023 to 2025. The table below shows the annual Asset Resilience Ratio data for Belite Bio Inc ADR.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 17.87% | $139.49 Million | $780.56 Million | -56.72pp |
| 2024-12-31 | 74.59% | $113.47 Million | $152.13 Million | -- |
| 2023-12-31 | 0.00% | $0.00 | $94.64 Million | -- |
About Belite Bio Inc ADR
Belite Bio, Inc, a clinical stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics targeting retinal degenerative eye diseases with unmet medical needs in the United States. Its lead product candidate is Tinlarebant (LBS-008), an orally administered, which is in phase 3 clinical trial as an early intervention for maintaining the health and … Read more